Clinical trials: Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
Heart Failure With Reduced Ejection Fraction
EHR Nudges to Improve Quality of Care in HF
The purpose of this pilot feasibility study is to test a pharmacist-facing clinical decision support tool designed to increase adherence to guideline-directed medical therapy and evaluate the tool using the Reach, Effectiveness…
- Trial name
- NCT06103565
- Testing
- Clinical Decision Support Tool
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Heart Failure
Impact of Vericiguat on Hemodynamics of Heart Failure
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for patients with heart failure. In a large randomized controlled trial, this drug was found to help patients with heart failure live longer…
- Trial name
- NCT05704478
- Testing
- Vericiguat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Heart Failure
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart…
- Trial name
- NCT06704633
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Tanzania
- Volunteers
- 298 people
- Sponsor
- Martin Rohacek
Assessment of the RV Function in Patients With Heart Faliure
Right Ventricular Function in Heart Failure
Only a few studies evaluated the RV systolic function in the three categories of HF, regarding the importance of understanding changes in RV function on clinical presentation and outcome; it was essential to understand the…
- Trial name
- NCT03641599
- Testing
- echocardiography
- Volunteers
- 150 people
- Sponsor
- shaimaa Mostafa
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Heart Failure With Reduced Ejection Fraction
Efficacy of Remote Monitoring of Patients With Heart Failure and Reduced Ejection Fraction by Using Caaring® Software
The goal of this clinical trial investigation with device is to determinate the effectiveness of remote monitoring of patients with heart failure with reduced ejection fraction heart (EFS40%) using Caaring® software.
- Trial name
- (CAARdioRING) (NCT06920160)
- Testing
- software Caaring (remote monitoring app)
- Where
- 2 sites in Spain
- Volunteers
- 196 people
- Sponsor
- Persei Vivarium
Chronic Stable Heart Failure
Qishenyiqi for Ventricular Remodeling After Myocardial Infarction
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported.
- Trial name
- NCT06699407
- Testing
- Qishenyiqi dripping pills
- Where
- 3 sites in China
- Volunteers
- 210 people
- Sponsor
- Qilu Hospital of Shandong University
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
- Trial name
- GOAL-HF2 (NCT07584967)
- Testing
- AC01
- Volunteers
- 400 people
- Sponsor
- AnaCardio AB
Heart Failure, Mortality
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice.
- Trial name
- PARADE-HF (NCT05329727)
- Testing
- Angiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
- Where
- South Korea
- Volunteers
- 1,000,000 people
- Sponsor
- Wonju Severance Christian Hospital
HFrEF - Heart Failure With Reduced Ejection Fraction
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- Vsling III (NCT06002386)
- Testing
- Vsling
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Cardiac Success
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
HFrEF - Heart Failure With Reduced Ejection Fraction, Guideline Adherence
Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4…
- Trial name
- IMPLEMENT HF (NCT07702760)
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Jasper Brugts MD PhD
Heart Failure With Reduced Ejection Fraction
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in…
- Trial name
- GOAL-HF1 (NCT05642507)
- Testing
- AC01
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 58 people
- Sponsor
- AnaCardio AB
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Vericiguat and Exercise Hemodynamics in Patients With HFrEF
Heart failure with reduced ejection fraction (HFrEF) is associated with impaired exercise capacity and abnormal exercise hemodynamics despite contemporary guideline-directed medical therapy (GDMT).
- Trial name
- EVERHETT-HF (NCT07697365)
- Testing
- Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Argyrios Ntalianis
Heart Failure With Reduced Ejection Fraction
Improving CRT Outcome With Non-Invasive Cardiac Mapping
The ICONIC-M study is a multicenter randomized controlled study to assess patient response to CRT comparing ECGI map guided left ventricular lead placement with empirical lead placement.
- Trial name
- ICONIC-M (NCT05564793)
- Testing
- Pre-implantation planning, Post-implantation assessment
- Where
- 11 sites in Netherlands, Portugal and 2 more
- Volunteers
- 330 people
- Sponsor
- EP Solutions SA
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05952089
- Testing
- Danicamtiv, Midazolam
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
Alleviant ALLAY-HFrEF Study
Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in…
- Trial name
- NCT06812533
- Testing
- Alleviant ALV1 System
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 350 people
- Sponsor
- Alleviant Medical, Inc.
PASP
Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart Failure
Evaluate effect of Sacubitril-Valsartan on estimated pulmonary artery systolic pressure in patient with reduced ejection fraction heart failure
- Trial name
- NCT07814482
- Testing
- SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Aswan University